The DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index.
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors
Open accessAbstract
Multidrug resistance (MDR) is the dominant cause of the failure of cancer chemotherapy. The design of antitumor drugs that are able to evade MDR is rapidly evolving, showing that this area of biomedical research attracts great interest in the scientific community. The current review explores promising recent approaches that have been developed with the aim of circumventing or overcoming MDR. Encouraging results have been obtained in the investigation of the MDR-modulating properties of various classes of natural compounds and their analogues. Inhibition of P-gp or downregulation of its expression have proven to be the main mechanisms by which MDR can be surmounted. The use of hybrid molecules that are able to simultaneously interact with two or more cancer cell targets is currently being explored as a means to circumvent drug resistance. This strategy is based on the design of hybrid compounds that are obtained either by merging the structural features of separate drugs, or by conjugating two drugs or pharmacophores via cleavable/non-cleavable linkers. The approach is highly promising due to the pharmacokinetic and pharmacodynamic advantages that can be achieved over the independent administration of the two individual components. However, it should be stressed that the task of obtaining successful multivalent drugs is a very challenging one. The conjugation of anticancer agents with nitric oxide (NO) donors has recently been developed, creating a particular class of hybrid that can combat tumor drug resistance. Appropriate NO donors have been shown to reverse drug resistance via nitration of ABC transporters and by interfering with a number of metabolic enzymes and signaling pathways. In fact, hybrid compounds that are produced by covalently attaching NO-donors and antitumor drugs have been shown to elicit a synergistic cytotoxic effect in a variety of drug resistant cancer cell lines. Another strategy to circumvent MDR is based on nanocarrier-mediated transport and the controlled release of chemotherapeutic drugs and P-gp inhibitors. Their pharmacokinetics are governed by the nanoparticle or polymer carrier and make use of the enhanced permeation and retention (EPR) effect, which can increase selective delivery to cancer cells. These systems are usually internalized by cancer cells via endocytosis and accumulate in endosomes and lysosomes, thus preventing rapid efflux. Other modalities to combat MDR are described in this review, including the pharmaco-modulation of acridine, which is a well-known scaffold in the development of bioactive compounds, the use of natural compounds as means to reverse MDR, and the conjugation of anticancer drugs with carriers that target specific tumor-cell components. Finally, the outstanding potential of in silico structure-based methods as a means to evaluate the ability of antitumor drugs to interact with drug transporters is also highlighted in this review. Structure-based design methods, which utilize 3D structural data of proteins and their complexes with ligands, are the most effective of the in silico methods available, as they provide a prediction regarding the interaction between transport proteins and their substrates and inhibitors. The recently resolved X-ray structure of human P-gp can help predict the interaction sites of designed compounds, providing insight into their binding mode and directing possible rational modifications to prevent them from becoming P-gp drug substrates. In summary, although major efforts were invested in the search for new tools to combat drug resistant tumors, they all require further implementation and methodological development. Further investigation and progress in the abovementioned strategies will provide significant advances in the rational combat against cancer MDR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Natural products as sources of new drugs from 1981 to 2014
Newman, D. J., & Cragg, G. M. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b01055 · Cited by 5,858
Panche, A. N., Diwan, A. D., & Chandra, S. R. (2016) · Journal of Nutritional Science · doi:10.1017/jns.2016.41 · Cited by 5,298
Natural products as sources of new drugs over the 30 years from 1981 to 2010
Newman, D. J., & Cragg, G. M. (2012) · Journal of Natural Products · doi:10.1021/np200906s · Cited by 4,687
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Nitric oxide and the immune response
Bogdan, C. (2001) · Nature Immunology · doi:10.1038/ni1001-907 · Cited by 3,447
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Danhier, F., Feron, O., & Préat, V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.027 · Cited by 2,800
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
The re-emergence of natural products for drug discovery in the genomics era
Harvey, A. L., Edrada-Ebel, R., & Quinn, R. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4510 · Cited by 2,572
Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,485
Progress and challenges towards targeted delivery of cancer therapeutics
Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-03705-y · Cited by 2,220
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116 · cited 1×
“Many cytotoxic agents cross biomembranes and enter cells via passive diffusion (Tredan et al., 2007).”
BackgroundRole of hypoxia in cancer therapy by regulating the tumor microenvironment
Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., & Shu, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1089-9 · Cited by 2,054
Flavonoids: biosynthesis, biological functions, and biotechnological applications
Falcone Ferreyra, M. L., Rius, S. P., & Casati, P. (2012) · Frontiers in Plant Science · doi:10.3389/fpls.2012.00222 · Cited by 1,831
Wink, D. A., & Mitchell, J. B. (1998) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(98)00092-6 · Cited by 1,606
The role of glutathione-S-transferase in anti-cancer drug resistance
Townsend, D. M., & Tew, K. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206940 · Cited by 1,353
Nitric oxide donors: chemical activities and biological applications
Wang, P. G., Xian, M., Tang, X., Wu, X., Wen, Z., Cai, T., & Janczuk, A. J. (2002) · Chemical Reviews · doi:10.1021/cr000040l · Cited by 1,337
The role of nitric oxide in tumour progression
Fukumura, D., Kashiwagi, S., & Jain, R. K. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1910 · Cited by 1,259
Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery
Thomford, N. E., Senthebane, D. A., Rowe, A., Munro, D., Seele, P., Maroyi, A., & Dzobo, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061578 · Cited by 1,241
Drug resistance and combating drug resistance in cancer
Wang, X., Zhang, H., & Chen, X. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.10 · Cited by 1,085
Feher, M., & Schmidt, J. M. (2003) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci0200467 · Cited by 927
Nitric Oxide: Pathophysiological Mechanisms
Gross, S. S., & Wolin, M. S. (1995) · Annual Review of Physiology · doi:10.1146/annurev.ph.57.030195.003513 · Cited by 888
Natural products: An evolving role in future drug discovery
Mishra, B. B., & Tiwari, V. K. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.07.057 · Cited by 860
Photochemistry and photophysics
Rabek, J. F. (1982) · Medical Entomology and Zoology · Cited by 856
(2002) · PubMed · Cited by 840
Simulation of water transport through a lipid membrane
Marrink, S.-J., & Berendsen, H. J. C. (1994) · The Journal of Physical Chemistry · doi:10.1021/j100066a040 · Cited by 837
MicroRNA silencing for cancer therapy targeted to the tumour microenvironment
Cheng, C. J., Bahal, R., Babar, I. A., Pincus, Z., Barrera, F., Liu, C., Svoronos, A., Braddock, D. T., Glazer, P. M., Engelman, D. M., et al. (2015) · Nature · doi:10.1038/nature13905 · Cited by 823
Li, W., Zhang, H., Assaraf, Y. G., Zhao, K., Xu, X., Xie, J., Yang, D.-H., & Chen, Z.-S. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.05.001 · Cited by 673
Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes
Altenberg, B., & Greulich, K. O. (2004) · Genomics · doi:10.1016/j.ygeno.2004.08.010 · Cited by 659
Biochemistry of Peroxynitrite and Protein Tyrosine Nitration
Ferrer-Sueta, G., Campolo, N., Trujillo, M., Bartesaghi, S., Carballal, S., Romero, N., Alvarez, B., & Radi, R. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00568 · Cited by 640
Cisplatin resistance and opportunities for precision medicine
Amable, L. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.001 · Cited by 589
Nitric Oxide: A New Paradigm for Second Messengers
Kerwin, J. F., Lancaster, J. R., & Feldman, P. L. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00022a001 · Cited by 565
Teicher, B. A. (1994) · Cancer and Metastasis Reviews · doi:10.1007/bf00689633 · Cited by 563
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Self-citationHummer, G. (2005) · New Journal of Physics · doi:10.1088/1367-2630/7/1/034 · Cited by 527
Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance
Shapira, A., Livney, Y. D., Broxterman, H. J., & Assaraf, Y. G. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.003 · Cited by 504
Lysosomes as mediators of drug resistance in cancer
Zhitomirsky, B., & Assaraf, Y. G. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.004 · Cited by 482
Multiple Drug Resistance Mechanisms in Cancer
Baguley, B. C. (2010) · Molecular Biotechnology · doi:10.1007/s12033-010-9321-2 · Cited by 478
Glucose transporters: expression, regulation and cancer
MEDINA, R. A., & OWEN, G. I. (2002) · Biological Research · doi:10.4067/s0716-97602002000100004 · Cited by 472
Structural insight into substrate and inhibitor discrimination by human P-glycoprotein
Alam, A., Kowal, J., Broude, E., Roninson, I., & Locher, K. P. (2019) · Science · doi:10.1126/science.aav7102 · Cited by 469
Antibody-Drug Conjugate-Based Therapeutics: State of the Science
Birrer, M. J., Moore, K. N., Betella, I., & Bates, R. C. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz035 · Cited by 439
Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance
Gonen, N., & Assaraf, Y. G. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.07.002 · Cited by 437
Interpretation of nonelectrolyte partition coefficients between dimyristoyl lecithin and water
Diamond, J. M., & Katz, Y. (1974) · The Journal of Membrane Biology · doi:10.1007/bf01870176 · Cited by 418
Structure of the human multidrug transporter ABCG2
Taylor, N. M. I., Manolaridis, I., Jackson, S. M., Kowal, J., Stahlberg, H., & Locher, K. P. (2017) · Nature · doi:10.1038/nature22345 · Cited by 418
Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects
Huang, Z., Fu, J., & Zhang, Y. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01672 · Cited by 406
Glucose Conjugation for the Specific Targeting and Treatment of Cancer
Calvaresi, E. C., & Hergenrother, P. J. (2013) · Chemical Science · doi:10.1039/c3sc22205e · Cited by 398
Adams, B. K., Ferstl, E. M., Davis, M. C., Herold, M., Kurtkaya, S., Camalier, R. F., Hollingshead, M. G., Kaur, G., Sausville, E. A., Rickles, F. R., et al. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.05.006 · Cited by 392
Dai, C.-L., Tiwari, A. K., Wu, C.-P., Su, X.-D., Wang, S.-R., Liu, D.-G., Ashby, C. R., Huang, Y., Robey, R. W., Liang, Y.-J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0499 · Cited by 386
Park, J., Choi, Y., Chang, H., Um, W., Ryu, J. H., & Kwon, I. C. (2019) · Theranostics · doi:10.7150/thno.37198 · Cited by 382
Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance
Gotink, K. J., Broxterman, H. J., Labots, M., de Haas, R. R., Dekker, H., Honeywell, R. J., Rudek, M. A., Beerepoot, L. V., Musters, R. J., Jansen, G., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1667 · Cited by 345
Natural products as multidrug resistance modulators in cancer
Kumar, A., & Jaitak, V. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.027 · Cited by 334
Liang, G., Shao, L., Wang, Y., Zhao, C., Chu, Y., Xiao, J., Zhao, Y., Li, X., & Yang, S. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.10.044 · Cited by 331
Patil, Y., Sadhukha, T., Ma, L., & Panyam, J. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.01.021 · Cited by 317
Shi, Z., Peng, X.-X., Kim, I.-W., Shukla, S., Si, Q.-S., Robey, R. W., Bates, S. E., Shen, T., Ashby, C. R., Fu, L.-W., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2686 · Cited by 315
Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance
Bar-Zeev, M., Livney, Y. D., & Assaraf, Y. G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.05.002 · Cited by 314
Development of a new permeability assay using low‐efflux MDCKII cells
Di, L., Whitney‐Pickett, C., Umland, J. P., Zhang, H., Zhang, X., Gebhard, D. F., Lai, Y., Federico, J. J., Davidson, R. E., Smith, R., et al. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22674 · Cited by 313
Collateral sensitivity as a strategy against cancer multidrug resistance
Pluchino, K. M., Hall, M. D., Goldsborough, A. S., Callaghan, R., & Gottesman, M. M. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.03.002 · Cited by 305
Javanbakht, S., & Namazi, H. (2018) · Materials Science and Engineering: C · doi:10.1016/j.msec.2018.02.010 · Cited by 302
Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets
Kopecka, J., Trouillas, P., Gašparović, A. Č., Gazzano, E., Assaraf, Y. G., & Riganti, C. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100670 · Cited by 291
Self-citationRiganti, C., Miraglia, E., Viarisio, D., Costamagna, C., Pescarmona, G., Ghigo, D., & Bosia, A. (2005) · Cancer Research · doi:10.1158/0008-5472.516.65.2 · Cited by 271
Wang, Z., Deng, X., Ding, J., Zhou, W., Zheng, X., & Tang, G. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.11.003 · Cited by 269
Taylor, S., Spugnini, E. P., Assaraf, Y. G., Azzarito, T., Rauch, C., & Fais, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.08.004 · Cited by 259
The biphasic nature of nitric oxide responses in tumor biology
Ridnour, L. A., Thomas, D. D., Donzelli, S., Espey, M. G., Roberts, D. D., Wink, D. A., & Isenberg, J. S. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.1329 · Cited by 247
An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer Chemotherapy
Takara, K., Sakaeda, T., & Okumura, K. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206775201965 · Cited by 236
Zhitomirsky, B., & Assaraf, Y. G. (2015) · Oncotarget · doi:10.18632/oncotarget.2732 · Cited by 225
Nitric oxide donors: Novel cancer therapeutics (Review)
Huerta (1992) · international Journal of Oncology · doi:10.3892/ijo_00000079 · Cited by 222
P-glycoprotein Mediates Drug Resistance via a Novel Mechanism Involving Lysosomal Sequestration
Yamagishi, T., Sahni, S., Sharp, D. M., Arvind, A., Jansson, P. J., & Richardson, D. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.514091 · Cited by 220
Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets
Skok, Ž., Zidar, N., Kikelj, D., & Ilaš, J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00726 · Cited by 217
Self-citationDohse, M., Scharenberg, C., Shukla, S., Robey, R. W., Volkmann, T., Deeken, J. F., Brendel, C., Ambudkar, S. V., Neubauer, A., & Bates, S. E. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.031302 · Cited by 216
Inhibition of P-Glycoprotein Function and Expression by Kaempferol and Quercetin
Limtrakul, P., Khantamat, O., & Pintha, K. (2005) · Journal of Chemotherapy · doi:10.1179/joc.2005.17.1.86 · Cited by 210
Family of pH (low) insertion peptides for tumor targeting
Weerakkody, D., Moshnikova, A., Thakur, M. S., Moshnikova, V., Daniels, J., Engelman, D. M., Andreev, O. A., & Reshetnyak, Y. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303708110 · Cited by 208
Rationally designed nanovehicles to overcome cancer chemoresistance
Livney, Y. D., & Assaraf, Y. G. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.006 · Cited by 205
The arginine‐nitric oxide pathway: A target for new drugs
Kerwin, J. F., & Heller, M. (1994) · Medicinal Research Reviews · doi:10.1002/med.2610140103 · Cited by 204
Yasuda, H. (2008) · Nitric Oxide · doi:10.1016/j.niox.2008.04.026 · Cited by 198
Cancer Chemoprevention and Piperine: Molecular Mechanisms and Therapeutic Opportunities
Rather, R. A., & Bhagat, M. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00010 · Cited by 198
Kim, J., Yung, B. C., Kim, W. J., & Chen, X. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.12.026 · Cited by 190
Constant-pH Molecular Dynamics Simulations for Large Biomolecular Systems
Radak, B. K., Chipot, C., Suh, D., Jo, S., Jiang, W., Phillips, J. C., Schulten, K., & Roux, B. (2017) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.7b00875 · Cited by 190
Molecular basis of resistance to proteasome inhibitors in hematological malignancies
Niewerth, D., Jansen, G., Assaraf, Y. G., Zweegman, S., Kaspers, G. J. L., & Cloos, J. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.12.001 · Cited by 189
Chung, M., Liu, H., Lin, K., Chia, W., & Sung, H. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201504444 · Cited by 185
Exosomes as Drug Carriers for Cancer Therapy
Pullan, J. E., Confeld, M. I., Osborn, J. K., Kim, J., Sarkar, K., & Mallik, S. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00104 · Cited by 181
Wink, M., Ashour, M. L., & El-Readi, M. Z. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00130 · Cited by 177
Vrettos, E. I., Mező, G., & Tzakos, A. G. (2018) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.14.80 · Cited by 175
Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer
Joshi, P., Vishwakarma, R. A., & Bharate, S. B. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.047 · Cited by 174
Patel, N. R., Rathi, A., Mongayt, D., & Torchilin, V. P. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.05.082 · Cited by 173
Nanoparticles for Cancer Targeting: Current and Future Directions
Swain, S., Sahu, P., Beg, S., & Babu, S. (2016) · Current Drug Delivery · doi:10.2174/1567201813666160713121122 · Cited by 169
Nitric Oxide-Mediated Regulation of Chemosensitivity in Cancer Cells
Matthews, N. E., Adams, M. A., Maxwell, L. R., Gofton, T. E., & Graham, C. H. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1879 · Cited by 168
Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis
Zhitomirsky, B., & Assaraf, Y. G. (2017) · Oncotarget · doi:10.18632/oncotarget.15155 · Cited by 163
Xu, K., Zhan, Y., Yuan, Z., Qiu, Y., Wang, H., Fan, G., Wang, J., Li, W., Cao, Y., Shen, X., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.017 · Cited by 160
Reversal of Multidrug Resistance in Cancer by Multi-Functional Flavonoids
Ye, Q., Liu, K., Shen, Q., Li, Q., Hao, J., Han, F., & Jiang, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00487 · Cited by 159
Targeting Strategies for the Combination Treatment of Cancer Using Drug Delivery Systems
Kydd, J. L., Jadia, R., Velpurisiva, P., Gad, A. P., Paliwal, S., & Rai, P. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9040046 · Cited by 158
Bonavida, B., Baritaki, S., Huerta‐Yépez, S., Vega, M. I., Chatterjee, D., & Yeung, K. C. (2008) · Nitric Oxide · doi:10.1016/j.niox.2008.04.018 · Cited by 154
Mechanism of allosteric modulation of P-glycoprotein by transport substrates and inhibitors
Dastvan, R., Mishra, S., Peskova, Y. B., Nakamoto, R. K., & Mchaourab, H. S. (2019) · Science · doi:10.1126/science.aav9406 · Cited by 151
El-Readi, M. Z., Hamdan, D. I., Farrag, N. M., El-Shazly, A. M., & Wink, M. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.09.040 · Cited by 150
Kiziltepe, T., Hideshima, T., Ishitsuka, K., Ocio, E. M., Raje, N. S., Catley, L. P., Li, C., Trudel, L. J., Yasui, H., Vallet, S., et al. (2007) · Blood · doi:10.1182/blood-2006-10-052845 · Cited by 147
Redundant angiogenic signaling and tumor drug resistance
Gacche, R. N., & Assaraf, Y. G. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.01.002 · Cited by 144
Piperine as a Potential Anti-cancer Agent: A Review on Preclinical Studies
Manayi, A., Nabavi, S. M., Setzer, W. N., & Jafari, S. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170523120656 · Cited by 143
Extracellular acidity and increased exosome release as key phenotypes of malignant tumors
Logozzi, M., Spugnini, E. P., Mizzoni, D., Raimo, R. D., & Fais, S. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09783-8 · Cited by 140
Bonavida, B., & Baritaki, S. (2010) · Nitric Oxide · doi:10.1016/j.niox.2010.10.001 · Cited by 139
Muniswamy, V. J., Raval, N., Gondaliya, P., Tambe, V., Kalia, K., & Tekade, R. K. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.11.035 · Cited by 136
The ABC subfamily A transporters: Multifaceted players with incipient potentialities in cancer
Pasello, M., Giudice, A. M., & Scotlandi, K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.004 · Cited by 136
A High-Throughput Cell-Based Assay for Inhibitors of ABCG2 Activity
Henrich, C. J., Bokesch, H. R., Dean, M. C., Bates, S. E., Robey, R. W., Goncharova, E. I., Wilson, J. A., & McMahon, J. B. (2006) · SLAS DISCOVERY · doi:10.1177/1087057105284576 · Cited by 135
Li, S., Zhao, Q., Wang, B., Yuan, S., Wang, X., & Li, K. (2018) · Phytotherapy Research · doi:10.1002/ptr.6081 · Cited by 135
Structure–Kinetic Relationships of Passive Membrane Permeation from Multiscale Modeling
Dickson, C. J., Horn̆ák, V., Pearlstein, R. A., & Duca, J. S. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b11215 · Cited by 131
Wang, Y., Huang, X., Tang, Y., Zou, J., Wang, P., Zhang, Y., Si, W., Huang, W., & Dong, X. (2018) · Chemical Science · doi:10.1039/c8sc03386b · Cited by 131
Soe, Z. C., Kwon, J. B., Thapa, R. K., Ou, W., Nguyen, H. T., Gautam, M., Oh, K. T., Choi, H., Ku, S., Yong, C. S., et al. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11020063 · Cited by 130
Hybrids of Phenylsulfonylfuroxan and Coumarin as Potent Antitumor Agents
Liu, M.-M., Chen, X., Huang, Y.-Q., Feng, P., Guo, Y.-L., Yang, G. S., & Chen, Y. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500613m · Cited by 128
Colabufo, N. A., Berardi, F., Cantore, M., Contino, M., Inglese, C., Niso, M., & Perrone, R. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900743c · Cited by 127
Zhitomirsky, B., Yunaev, A., Kreiserman, R., Kaplan, A., Stark, M., & Assaraf, Y. G. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1227-0 · Cited by 126
Developments in Carbohydrate-Based Cancer Therapeutics
Hossain, F., & Andreana, P. R. (2019) · Pharmaceuticals · doi:10.3390/ph12020084 · Cited by 124
Leon, L. M., Gautier‐Isola, M., Allan, R., Ilié, M., Nottet, N., Pons, N., Paquet, A. C., Lebrigand, K., Truchi, M., Fassy, J., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0935-y · Cited by 124
Photoinduced Nitric Oxide Release from Nitrobenzene Derivatives
Suzuki, T., Nagae, O., Kato, Y., Nakagawa, H., Fukuhara, K., & Miyata, N. (2005) · Journal of the American Chemical Society · doi:10.1021/ja0512024 · Cited by 123
Sims, J. T., Ganguly, S. S., Bennett, H., Friend, J. W., Tepe, J., & Plattner, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055509 · Cited by 121
Chen, Z., Huang, C., Ma, T., Jiang, L., Tang, L., Shi, T., Zhang, S., Zhang, L., Zhu, P., Li, J., et al. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.03.040 · Cited by 121
Measuring Tumor Aggressiveness and Targeting Metastatic Lesions with Fluorescent pHLIP
Reshetnyak, Y. K., Yao, L., Zheng, S., Kuznetsov, S., Engelman, D. M., & Andreev, O. A. (2010) · Molecular Imaging and Biology · doi:10.1007/s11307-010-0457-z · Cited by 118
Scicinski, J. J., Oronsky, B. T., Ning, S., Knox, S. J., Peehl, D. M., Kim, M. M., Langecker, P. J., & Fanger, G. R. (2015) · Redox Biology · doi:10.1016/j.redox.2015.07.002 · Cited by 117
Curcumin as a Modulator of P-Glycoprotein in Cancer: Challenges and Perspectives
Lopes-Rodrigues, V., Sousa, E., & Vasconcelos, M. H. (2016) · Pharmaceuticals · doi:10.3390/ph9040071 · Cited by 116
Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency
Kutova, O. M., Guryev, E. L., Соколова, Е. А., Alzeibak, R., & Balalaeva, I. V. (2019) · Cancers · doi:10.3390/cancers11010068 · Cited by 116
Polymer-drug conjugates: current status and future trends
Greco, F., & Vicent, M. J. (2007) · Frontiers in bioscience · doi:10.2741/2882 · Cited by 113
Cao, Z., Li, W., Liu, R., Li, X., Li, H., Liu, L., Chen, Y., Lv, C., & Liu, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109340 · Cited by 113
Inhibition of P-Glycoprotein-Mediated Paclitaxel Resistance by Reversibly Linked Quinine Homodimers
Pires, M. M., Emmert, D., Hrycyna, C. A., & Chmielewski, J. A. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.050492 · Cited by 112
Frederiksen, L. J., Siemens, D. R., Heaton, J. P. W., Maxwell, L., ADAMS, M. A., & Graham, C. H. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000081126.71235.e0 · Cited by 107
Shami, P. J., Saavedra, J. E., Bonifant, C. L., Chu, J., Udupi, V., Malaviya, S., Carr, B. I., Kar, S., Wang, M., Jia, L., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060022h · Cited by 107
Ji, N., Yang, Y., Cai, C., Lei, Z., Wang, J., Gupta, P., Shukla, S., Ambudkar, S. V., Kong, D., & Chen, Z. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.007 · Cited by 106
Inhibition of anticancer drug efflux transporter P-glycoprotein by rosemary phytochemicals
Nabekura, T., Yamaki, T., Hiroi, T., Ueno, K., & Kitagawa, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.11.010 · Cited by 101
Vogus, D. R., Evans, M. A., Pusuluri, A., Barajas, A., Zhang, M., Krishnan, V., Nowak, M., Menegatti, S., Helgeson, M. E., Squires, T. M., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.016 · Cited by 100
Modulation of multidrug resistance in cancer cells by chelidonine and Chelidonium majus alkaloids
El-Readi, M. Z., Eid, S. Y., Ashour, M. L., Tahrani, A., & Wink, M. (2012) · Phytomedicine · doi:10.1016/j.phymed.2012.11.005 · Cited by 97
Bratasz, A., Weir, N. M., Parinandi, N. L., Zweier, J. L., Sridhar, R., Ignarro, L. J., & Kuppusamy, P. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511250103 · Cited by 97
Boo, S. D., Kopecka, J., Brusa, D., Gazzano, E., Matera, L., Ghigo, D., Bosìa, A., & Riganti, C. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-108 · Cited by 97
Self-citationZhou, Q., Hou, Y., Zhang, L., Wang, J., Qiao, Y., Guo, S., Fan, L., Yang, T., Zhu, L., & Wu, H. (2017) · Theranostics · doi:10.7150/thno.18607 · Cited by 97
Oxygen-mediated Regulation of Tumor Cell Invasiveness
Postovit, L.-M. M., ADAMS, M. A., Lash, G. E., Heaton, J. P. W., & Graham, C. H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204529200 · Cited by 96
Sen, R., Natarajan, K., Bhullar, J., Shukla, S., Fang, H.-B., Cai, L., Chen, Z., Ambudkar, S. V., & Baer, M. R. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0302 · Cited by 93
Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma
Azzarito, T., Venturi, G., Cesolini, A., & Fais, S. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.10.017 · Cited by 91
Zhang, J., Wang, L., Chan, H. F., Xie, W., Chen, S., He, C., Wang, Y., & Chen, M. (2017) · Scientific Reports · doi:10.1038/srep46057 · Cited by 91
Dynamic Protonation Dramatically Affects the Membrane Permeability of Drug-like Molecules
Yue, Z., Li, C., Voth, G. A., & Swanson, J. M. J. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b04387 · Cited by 90
Luca, A. D., Moroni, N., Serafino, A., Primavera, A., Pastore, A., Pedersen, J. Z., Petruzzelli, R., Farrace, M. G., Pierimarchi, P., Moroni, G., et al. (2011) · Biochemical Journal · doi:10.1042/bj20111333 · Cited by 88
de‐Freitas‐Junior, J. C. M., & Morgado‐Díaz, J. A. (2015) · Oncotarget · doi:10.18632/oncotarget.6283 · Cited by 87
Overcoming Multidrug Resistance in Human Cancer Cells by Natural Compounds
Nabekura, T. (2010) · Toxins · doi:10.3390/toxins2061207 · Cited by 86
Engineered collagen-binding serum albumin as a drug conjugate carrier for cancer therapy
Sasaki, K., Ishihara, J., Ishihara, A., Miura, R., Mansurov, A., Fukunaga, K., & Hubbell, J. A. (2019) · Science Advances · doi:10.1126/sciadv.aaw6081 · Cited by 83
Leonetti, A., Assaraf, Y. G., Veltsista, P. D., Hassouni, B. E., Tiseo, M., & Giovannetti, E. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.11.002 · Cited by 82
Bar-Zeev, M., Assaraf, Y. G., & Livney, Y. D. (2016) · Oncotarget · doi:10.18632/oncotarget.8019 · Cited by 81
Wang, Y., Zhang, Y., Zhang, G.-N., Rihani, S. B. A., Wei, M.-N., Gupta, P., Zhang, X., Shukla, S., Ambudkar, S. V., Kaddoumi, A., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.011 · Cited by 79
Gazzano, E., Rolando, B., Chegaev, K. Y., Salaroglio, I. C., Kopecka, J., Pedrini, I., Saponara, S., Sorge, M., Buondonno, I., Stella, B., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.042 · Cited by 79
Self-citationShim, J. S., Lee, H., Shin, J., & Kwon, H. J. (2003) · Cancer Letters · doi:10.1016/j.canlet.2003.08.036 · Cited by 78
Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands
Novohradský, V., Zerzánková, L., Štěpánková, J., Vrána, O., Raveendran, R., Gibson, D., Kašpárková, J., & Brabec, V. (2014) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2014.07.004 · Cited by 77
Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells
Mukai, M., Che, X., Furukawa, T., Sumizawa, T., Aoki, S., Ren, X., Haraguchi, M., Sugimoto, Y., Kobayashi, M., Takamatsu, H., et al. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01482.x · Cited by 76
SUN, L., Chen, W., Qu, L., Wu, J., & Jin, S. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1742 · Cited by 75
Chegaev, K. Y., Riganti, C., Lazzarato, L., Rolando, B., Guglielmo, S., Campia, I., Fruttero, R., Bosìa, A., & Gasco, A. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100302t · Cited by 75
Self-citationJangir, D. K., Dey, S. K., Kundu, S., & Mehrotra, R. (2012) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2012.05.005 · Cited by 74
Mitochondrial-Targeting Nitrooxy-doxorubicin: A New Approach To Overcome Drug Resistance
Riganti, C., Rolando, B., Kopecka, J., Campia, I., Chegaev, K. Y., Lazzarato, L., Federico, A., Fruttero, R., & Ghigo, D. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300311b · Cited by 74
Self-citationAi, Y., Kang, F., Huang, Z., Xue, X., Lai, Y., Peng, S., Tian, J., & Zhang, Y. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm5019302 · Cited by 71
Khoury, F. E., Corcos, L., Durand, S., Simon, B., & Jossic-Corcos, C. L. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3725 · Cited by 71
Huerta‐Yépez, S., Baritaki, S., Baay-Guzman, G. J., Hernández-Luna, M. A., Hernandez-Cueto, A., Vega, M. I., & Bonavida, B. (2012) · Nitric Oxide · doi:10.1016/j.niox.2012.12.001 · Cited by 70
Lei, Y., Tan, J., Wink, M., Ma, Y., Li, N., & Su, G. (2012) · Food Chemistry · doi:10.1016/j.foodchem.2012.09.059 · Cited by 69
Ma, Y., & Wink, M. (2008) · Phytomedicine · doi:10.1016/j.phymed.2007.11.028 · Cited by 69
Zhang, Y., Dang, M., Tian, Y., Zhu, Y., Liu, W., Tian, W., Su, Y., Ni, Q., Xu, C., Lu, N., et al. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b10840 · Cited by 69
Burns, K. E., Robinson, M. K., & Thévenin, D. (2015) · Molecular Pharmaceutics · doi:10.1021/mp500779k · Cited by 66
Liu, J., Li, C., Qu, W., Leslie, E. M., Bonifant, C. L., Buzard, G. S., Saavedra, J. E., Keefer, L. K., & Waalkes, M. P. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.709.3.6 · Cited by 66
Saneja, A., Khare, V. R., Alam, N., Dubey, R. D., & Gupta, P. N. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.865014 · Cited by 65
Demoin, D. W., Wyatt, L. C., Edwards, K. J., Abdel-Atti, D., Sarparanta, M. P., Pourat, J., Longo, V. A., Carlin, S. D., Engelman, D. M., Andreev, O. A., et al. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00306 · Cited by 65
Severe hypoxia induces complete antifolate resistance in carcinoma cells due to cell cycle arrest
Raz, S., Sheban, D., Gonen, N., Stark, M., Berman, B., & Assaraf, Y. G. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.39 · Cited by 64
Multiple Patterns of Resistance of Human Leukemia Cell Sublines to Amsacrine Analogues
Finlay, G. J., Baguley, B. C., Snow, K., & Judd, W. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.8.662 · Cited by 64
Eid, S. Y., El-Readi, M. Z., Eldin, E. E. M. N., Fatani, S. H., & Wink, M. (2013) · Phytomedicine · doi:10.1016/j.phymed.2013.07.019 · Cited by 63
Erlotinib antagonizes ABC transporters in acute myeloid leukemia
Lainey, É., Sébert, M., Thépot, S., Scoazec, M., Bouteloup, C., Leroy, C., de Botton, S., Galluzzi, L., Fenaux, P., & Kroemer, G. (2012) · Cell Cycle · doi:10.4161/cc.22382 · Cited by 63
Nitric oxide‐mediated regulation of hypoxia‐induced B16F10 melanoma metastasis
Postovit, L.-M. M., ADAMS, M. A., Lash, G. E., Heaton, J. P. W., & Graham, C. H. (2003) · International Journal of Cancer · doi:10.1002/ijc.11556 · Cited by 61
Chen, Y., Lee, Y., Huang, C., & Chang, L. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.09.007 · Cited by 61
Li, C., Kim, M.-H., Choi, H.-S., & Choi, J. (2011) · Archives of Pharmacal Research · doi:10.1007/s12272-011-1117-9 · Cited by 60
Wu, M., Li, H., Liu, R., Gao, X., Zhang, M., Liu, P., Fu, Z., Yang, J., Zhang‐Negrerie, D., & Gao, Q. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.01.016 · Cited by 58
Cui, Z., Li, X., Li, L., Zhang, B., Gao, C., Chen, Y., Tan, C., Liu, H., Xie, W., Yang, T., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.12.011 · Cited by 57
Sztandera, K., Działak, P., Marcinkowska, M., Stańczyk, M., Gorzkiewicz, M., Janaszewska, A., & Klajnert‐Maculewicz, B. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2673-9 · Cited by 57
Li, X., Yang, X., Lin, Z., Wang, D., Mei, D., He, B., Wang, X., Wang, X., Zhang, Q., & Gao, W. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.04.018 · Cited by 56
Akkapeddi, P., Fragoso, R., Hixon, J. A., Ramalho, A. S., Oliveira, M. L., Carvalho, T., Gloger, A., Matasci, M., Corzana, F., Durum, S. K., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0434-8 · Cited by 56
Song, Q., Chuan, X., Chen, B., He, B., Zhang, H., Dai, W., Wang, X., & Zhang, Q. (2015) · Drug Delivery · doi:10.3109/10717544.2015.1028601 · Cited by 55
Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity
Rijpma, S. R., van den Heuvel, J. J. M. W., van der Velden, M., Sauerwein, R. W., Rüssel, F. G. M., & Koenderink, J. B. (2014) · Malaria Journal · doi:10.1186/1475-2875-13-359 · Cited by 54
Al-Akra, L., Bae, D.-H., Sahni, S., Huang, M., Park, K. C., Lane, D. J. R., Jansson, P. J., & Richardson, D. R. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.772699 · Cited by 54
Guo, Y.-L., Wang, Y., Li, H., Wang, K., Wan, Q., Li, J. X., Zhou, Y., & Chen, Y. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00125 · Cited by 54
Chen, J., Li, D., Li, W., Yin, J., Zhang, Y., Yuan, Z., Gao, C., Liu, F., & Jiang, Y. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.06.016 · Cited by 54
Yi, J.-M., Zhang, X., Huan, X., Song, S., Wang, W., Tian, Q.-T., Sun, Y.-M., Chen, Y., Ding, J., Wang, Y.-Q., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3264 · Cited by 53
Phenylsulfonylfuroxans as Modulators of Multidrug-Resistance-Associated Protein-1 and P-Glycoprotein
Fruttero, R., Crosetti, M., Chegaev, K. Y., Guglielmo, S., Gasco, A., Berardi, F., Niso, M., Perrone, R., Panaro, M. A., & Colabufo, N. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100066y · Cited by 53
Self-citationQuest for Efficacious Next-Generation Taxoid Anticancer Agents and Their Tumor-Targeted Delivery
Ojima, I., Wang, X., Jing, Y., & Wang, C. (2018) · Journal of Natural Products · doi:10.1021/acs.jnatprod.7b01012 · Cited by 53
Tian, Y., Mi, G., Chen, Q., Chaurasiya, B., Li, Y., Shi, D., Zhang, Y., Webster, T. J., Sun, C., & Shen, Y. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b15147 · Cited by 51
RhoA Silencing Reverts the Resistance to Doxorubicin in Human Colon Cancer Cells
Doublier, S., Riganti, C., Voena, C., Costamagna, C., Aldieri, E., Pescarmona, G., Ghigo, D., & Bosìa, A. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0251 · Cited by 50
Kogias, E., Osterberg, N., Baumer, B., Psarras, N., Koentges, C., Papazoglou, A., Saavedra, J. E., Keefer, L. K., & Weyerbrock, A. (2011) · International Journal of Cancer · doi:10.1002/ijc.26106 · Cited by 48
Cincinelli, R., Musso, L., Dallavalle, S., Artali, R., Tinelli, S., Colangelo, D., Zunino, F., Cesare, M. D., Beretta, G. L., & Zaffaroni, N. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.02.022 · Cited by 48
Self-citationMolecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors
Yaghmaie, M., & Yeung, C. C. S. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00543-7 · Cited by 48
Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance
Chegaev, K. Y., Fraix, A., Gazzano, E., Abd-Ellatef, G. E. F., Blangetti, M., Rolando, B., Sabrina Conoci, A., Riganti, C., Fruttero, R., Gasco, A., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00016 · Cited by 47
Self-citationEpigenetic and antitumor effects of platinum(IV)-octanoato conjugates
Novohradský, V., Zanellato, I., Marzano, C., Prachařová, J., Kašpárková, J., Gibson, D., Gandin, V., Osella, D., & Brabec, V. (2017) · Scientific Reports · doi:10.1038/s41598-017-03864-w · Cited by 45
Čondić‐Jurkić, K., Subramanian, N., Mark, A. E., & O’Mara, M. L. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191882 · Cited by 45
Structure–Activity Relationships of Tariquidar Analogs as Multidrug Resistance Modulators
Pajeva, I. K., & Wiese, M. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9118-z · Cited by 44
Self-citationMuir, C., Adams, M. A., & Graham, C. H. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9076-9 · Cited by 43
Sandeep, M. S., Vemulapalli, S., Puneeth, Y., Pingili, R. B., & Babu, K. N. (2013) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2013.819885 · Cited by 43
Villar, V. H., Vögler, O., Martínez-Serra, J., Ramos, R. F., Fariñas, S. C., Gutierrez, A. M., Barceló, F., Martín‐Broto, J., & Alemany, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037735 · Cited by 41
Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors
Cincinelli, R., Musso, L., Artali, R., Guglielmi, M. B., Bianchino, E., Cardile, F., Colelli, F., Pisano, C., & Dallavalle, S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.021 · Cited by 41
Self-citationProtein Contacts and Ligand Binding in the Inward‐Facing Model of Human P‐Glycoprotein
Pajeva, I. K., Hanl, M., & Wiese, M. (2013) · ChemMedChem · doi:10.1002/cmdc.201200491 · Cited by 40
Self-citationCai, B., Liao, A., Lee, K., Ban, J.-S., Yang, H.-S., Im, Y. J., & Chun, C. (2016) · Steroids · doi:10.1016/j.steroids.2016.10.006 · Cited by 40
Zhang, W., Guo, J., Li, S., Ma, T., Xu, D., Han, C., Liu, F., Yu, W., & Kong, L. (2017) · Scientific Reports · doi:10.1038/srep46352 · Cited by 40
Zhang, Q., Zhai, S., Li, L., Li, X., Zhou, H., Liu, A., Su, G., Mu, Q., Du, Y., & Yan, B. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.05.019 · Cited by 39
Glycopeptide dendrimer colchicine conjugates targeting cancer cells
Johansson, E. M. V., Dubois, J., Darbre, T., & Reymond, J. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.04.026 · Cited by 39
Cited by
Mechanisms of Multidrug Resistance in Cancer Chemotherapy
Bukowski, K., Kciuk, M., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093233 · Cited by 1,757
Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
Kciuk, M., Gielecińska, A., Mujwar, S., Kołat, D., Kałuzińska-Kołat, Ż., Celik, I., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040659 · Cited by 810
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
Theranostic Fluorescent Probes
Sharma, A., Verwilst, P., Li, M., Ma, D., Singh, N., Yoo, J., Kim, Y., Yang, Y., Zhu, J.-H., Huang, H., et al. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00778 · Cited by 499
Asymmetric organocatalysis: an enabling technology for medicinal chemistry
Han, B., He, X.-H., Liu, Y.-Q., He, G., Peng, C., & Li, J.-L. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00196a · Cited by 402
Metadata
- Authors
- Dallavalle, S., Dobričić, V., Lazzarato, L., Gazzano, E., Machuqueiro, M., Pajeva, I., Tsakovska, I., Zidar, N., & Fruttero, R.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 50
- Pages
- 100682
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W3005521705
- Cited by
- 318
- References
- 240
- FWCI
- 14.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.